Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options
Alcohol and opioid misuse, and depression on the rise because of COVID-19 prompts response to address urgent needMorristown, New Jersey, September 9, 2020 – Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alcohol misuse respectively. OXD01, a digital therapy for the treatment of opioid use disorders, will also be available in the US in Q4 2020 through the partnership. In April of this year, the FDA released an enforcement policy for digital